FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to molecular biology, and can be used in neurology and endocrinology. A ligand-binding domain of a soluble corticotrophin release factor receptor type 2 (sCRFR2) which is characterised by an ability to inhibit said receptor activity in the presence of a ligand selected from a group including the corticotrophin release factor, urocortin-1, urocortin-2, urocortin-3 and stresscophin is produced. What is offered is using the produced sCRFR2 or its conjugate with polyethylene glycol as a CRFR2 activity modulator and/or a pharmacological effect of a bound ligand.
EFFECT: production of the new compositions.
6 cl, 17 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| YEAST PROTEIN DISPLAY IN THE PERIPLASMATIC SPACE | 2018 |
|
RU2802770C2 |
| IDENTIFICATION OF MOLECULES MODULATING PROTEIN-PROTEIN INTERACTION | 2008 |
|
RU2476891C2 |
| G-PROTEIN COUPLED RECEPTORS DROSOPHILA, NUCLEIC ACIDS AND RELATED METHODS | 2003 |
|
RU2326385C2 |
| G-PROTEIN-CONJUGATED RECEPTOR WHICH HAVING ALTERED LIGAND AFFINITY AND APPLICATION THEREOF | 2008 |
|
RU2468035C2 |
| VECTORS CONDITIONALLY EXPRESSING THERAPEUTIC PROTEINS, HOST CELLS COMPRISING THE VECTORS, AND USES THEREOF | 2011 |
|
RU2612788C2 |
| PRODUCING GLYCOPROTEINS | 2007 |
|
RU2463345C2 |
| METHOD OF AGENT IDENTIFICATION | 2003 |
|
RU2325652C2 |
| CHIMERIC ANTIGENIC RECEPTORS WITH MND-PROMOTER | 2015 |
|
RU2708311C2 |
| UROCORTIN-III, ITS ANALOG (VARIANTS) AND PHARMACEUTICAL COMPOSITION | 2002 |
|
RU2305109C2 |
| MODIFIED PROTEINS, CONSTRUCTED TOXINS AND METHODS FOR PRODUCTION THEREOF | 2002 |
|
RU2305684C2 |
